All In Biotech

Drug Trial Radar · NCT06209281

A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops in Slowing the Progression of Myopia in Children

Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 526 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

526

Actual

Start

May 13, 2022

Primary completion

Aug 20, 2023

Study completion Dec 2025

Sponsor

Sponsor type
Industry
First posted
Jan 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a randomized, double-blind, placebo-controlled, multicenter, superiority design, phase III clinical trial to compare the efficacy and safety of two low-concentration atropine sulfate eye drops versus placebo in delaying myopia progression in children.

Conditions

  • Myopia

Interventions

  • Lower dose atropine sulfate eye dropsDrug

    Administer to eyes

  • Low dose atropine sulfate eye dropsDrug

    Administer to eyes

  • placeboDrug

    Administer to eyes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cycloplegic Autorefraction(low)Time frame: twelve months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eye & ENT Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.